#United Kingdom #Oxford #AI Technology #Heart Failure #Ultromics

Ultromics Secures $55 Million in Series C Funding to Combat Undiagnosed Heart Failure

Ultromics, a leading innovator in artificial intelligence solutions for cardiology, has announced the successful closure of its Series C financing round, raising $55 million. This funding is vital for enhancing the detection of heart failure, a condition that remains undiagnosed in a significant number of patients. With this investment, Ultromics aims to expand its AI-driven technology, which can identify the subtle signals of heart failure from standard echocardiograms, thereby aiding clinicians in delivering timely interventions.

The Series C round was co-led by notable investors including LG, Allegis Capital, and Lightrock, alongside continued backing from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University. This substantial financial boost will facilitate Ultromics in scaling its revolutionary heart failure diagnostics across hospitals nationwide, making it an integral aspect of cardiac care across various healthcare settings.

Founded at the University of Oxford, Ultromics leverages extensive clinical research and a vast dataset of echocardiograms, having already analyzed over 430,000 scans to date. The company has made significant strides in addressing one of the most pressing challenges in healthcare: up to 64% of heart failure cases, particularly forms that are more challenging to detect, go unnoticed. Their flagship product, the EchoGo® platform, has received FDA clearance and Medicare reimbursement, reinforcing its adoption in top U.S. hospitals.

The Impact of Underdiagnosed Heart Failure

Heart failure is a growing concern in the U.S., responsible for driving healthcare costs that exceed $30 billion annually, with projections suggesting this could rise beyond $70 billion by 2030. Clinicians often face the challenge of interpreting echocardiograms subjectively, which can lead to missed or delayed diagnoses. Especially in complex cases like HFpEF (heart failure with preserved ejection fraction) and cardiac amyloidosis, patients frequently experience worsening symptoms before receiving appropriate care.

Ultromics intends to bridge this diagnostic gap through its AI capabilities, which allow for the extraction of crucial disease indicators from existing echocardiogram data. This approach enables earlier and more accurate detection without necessitating new hardware, seamlessly integrating into existing workflows in clinical settings. The EchoGo® technology excels at producing real-time probability scores, greatly enhancing the ability of cardiologists to identify high-risk patients earlier than traditional methods.

Dr. Ross Upton, the CEO and founder of Ultromics, emphasizes the importance of their work: “The reality is, hospitals already have the data; they just haven't had the tools to extract the more subtle diagnostic signals from it. By harnessing routine echocardiograms with AI, we're assisting clinicians in identifying high-risk patients sooner, allowing for interventions that prevent disease progression.”

Advancing Cardiac Care

In recent years, Ultromics has expanded its platform capabilities significantly, rolling out new features that further boost its diagnostic efficacy. After receiving FDA Breakthrough Device clearance for its amyloidosis detection module in late 2024, the company introduced the EchoGo® Score feature in 2025, an enhancement that incorporates AI-driven probability scoring. These advances are crucial as they underscore Ultromics' commitment to improving the standard of care in cardiology, thereby elevating patient outcomes across the board.

The company’s innovative technology has been validated through various peer-reviewed studies, demonstrating its effectiveness in enhancing diagnosis accuracy. For instance, one significant study found that EchoGo® improved the detection rates of HFpEF by 73.6% compared to traditional risk assessment models.

Future Projections

As Ultromics continues to strengthen its presence within the U.S. healthcare market, partnerships with prestigious institutions such as UChicago Medicine and Mayo Clinic are fostering a regional cluster of clinical excellence. With a strategic focus on high-prevalence regions, Ultromics aims to facilitate cost-effective, early intervention strategies that will alleviate the burden on both patients and healthcare systems.

Alastair Stewart from LG remarked, “Ultromics has positioned itself as a leader in the underserved cardiovascular disease market, and this successful Series C funding reflects the vast potential for advanced technology to transform how cardiovascular diseases are diagnosed and treated.” This new financial boost could not come at a more pivotal moment as healthcare practitioners seek effective solutions to combat the growing heart failure crisis.

With several definitive clinical studies backing their technology, Ultromics is poised to make a lasting impact on heart disease diagnostics and forge new paths in cardiac care. By capitalizing on the changing landscape of healthcare, they not only enhance diagnostic accuracy but also expand accessibility to specialists, potentially saving countless lives in the process.

For further information about Ultromics and its pioneering advancements in cardiology, visit their official website www.ultromics.com.